NextRNA Therapeutics, Inc. is a MA-based newly founded biotechnology company committed to leading the next revolution of RNA-directed therapeutics. Based on the foundational work of Carl Novina at Dana-Farber Cancer Institute, NextRNA has established a proprietary target and drug discovery engine that enables us to systematically identify disease-relevant long non-coding RNAs and their interacting proteins, and develop selective small molecules to drug RNA-protein interactions. The company is currently advancing two small molecule therapeutic programs in oncology and immunology. NextRNA has assembled a highly experienced and competent team of industry leaders, biology and chemistry experts, and drug developers, all driven by a common passion for working together and having an impact on science and patients.
